Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price gapped up before the market opened on Monday . The stock had previously closed at $5.21, but opened at $5.39. Mesoblast shares last traded at $5.48, with a volume of 106,631 shares trading hands.
Analysts Set New Price Targets
Several analysts have commented on the stock. StockNews.com cut shares of Mesoblast from a "hold" rating to a "sell" rating in a research report on Tuesday, April 2nd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Mesoblast in a research report on Friday, January 12th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Mesoblast has an average rating of "Hold" and an average price target of $13.67.
Check Out Our Latest Report on MESO
Mesoblast Trading Up 6.1 %
The company has a market cap of $630.81 million, a price-to-earnings ratio of -4.94 and a beta of 3.59. The firm's fifty day moving average price is $3.46 and its 200-day moving average price is $2.64.
Institutional Investors Weigh In On Mesoblast
A hedge fund recently bought a new stake in Mesoblast stock. Prosperity Wealth Management Inc. bought a new stake in Mesoblast Limited (NASDAQ:MESO - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 64,150 shares of the company's stock, valued at approximately $79,000. 1.43% of the stock is currently owned by institutional investors and hedge funds.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Further Reading
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
